The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternative...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lara Herrera, Silvia Santos, Miguel Angel Vesga, Tomas Carrascosa, Juan Carlos Garcia-Ruiz, Antonio Pérez-Martínez, Manel Juan, Cristina Eguizabal
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	CAR-NK CAR-T hematological cancer immunotherapy blood Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4ba5c4420bbb41e9b71bdae59fe70e56
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4ba5c4420bbb41e9b71bdae59fe70e56
record_format	dspace
spelling	oai:doaj.org-article:4ba5c4420bbb41e9b71bdae59fe70e562021-11-11T15:30:53ZThe Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers10.3390/cancers132154182072-6694https://doaj.org/article/4ba5c4420bbb41e9b71bdae59fe70e562021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5418https://doaj.org/toc/2072-6694Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternatives need to be used, such as immunotherapy targeting specific receptors of malignant cells. Among all the options, CAR (Chimeric antigen receptor)-based therapy has arisen as a new opportunity for refractory or relapsed hematological cancer patients. CARs were designed to be used along with T lymphocytes, creating CAR-T cells, but they are presenting such encouraging results that they are already in use as drugs. Nonetheless, their side-effects and the fact that it is not possible to infuse an allogenic CAR-T product without causing graft-versus-host-disease, have meant using a different cell source to solve these problems, such as Natural Killer (NK) cells. Although CAR-based treatment is a high-speed race led by CAR-T cells, CAR-NK cells are slowly (but surely) consolidating their position; their demonstrated efficacy and the lack of undesirable side-effects is opening a new door for CAR-based treatments. CAR-NKs are now in the field to stay.Lara HerreraSilvia SantosMiguel Angel VesgaTomas CarrascosaJuan Carlos Garcia-RuizAntonio Pérez-MartínezManel JuanCristina EguizabalMDPI AGarticleCAR-NKCAR-Thematological cancerimmunotherapybloodNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5418, p 5418 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CAR-NK CAR-T hematological cancer immunotherapy blood Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	CAR-NK CAR-T hematological cancer immunotherapy blood Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lara Herrera Silvia Santos Miguel Angel Vesga Tomas Carrascosa Juan Carlos Garcia-Ruiz Antonio Pérez-Martínez Manel Juan Cristina Eguizabal The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
description	Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternatives need to be used, such as immunotherapy targeting specific receptors of malignant cells. Among all the options, CAR (Chimeric antigen receptor)-based therapy has arisen as a new opportunity for refractory or relapsed hematological cancer patients. CARs were designed to be used along with T lymphocytes, creating CAR-T cells, but they are presenting such encouraging results that they are already in use as drugs. Nonetheless, their side-effects and the fact that it is not possible to infuse an allogenic CAR-T product without causing graft-versus-host-disease, have meant using a different cell source to solve these problems, such as Natural Killer (NK) cells. Although CAR-based treatment is a high-speed race led by CAR-T cells, CAR-NK cells are slowly (but surely) consolidating their position; their demonstrated efficacy and the lack of undesirable side-effects is opening a new door for CAR-based treatments. CAR-NKs are now in the field to stay.
format	article
author	Lara Herrera Silvia Santos Miguel Angel Vesga Tomas Carrascosa Juan Carlos Garcia-Ruiz Antonio Pérez-Martínez Manel Juan Cristina Eguizabal
author_facet	Lara Herrera Silvia Santos Miguel Angel Vesga Tomas Carrascosa Juan Carlos Garcia-Ruiz Antonio Pérez-Martínez Manel Juan Cristina Eguizabal
author_sort	Lara Herrera
title	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
title_short	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
title_full	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
title_fullStr	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
title_full_unstemmed	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
title_sort	race of car therapies: car-nk cells for fighting b-cell hematological cancers
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4ba5c4420bbb41e9b71bdae59fe70e56
work_keys_str_mv	AT laraherrera theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT silviasantos theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT miguelangelvesga theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT tomascarrascosa theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT juancarlosgarciaruiz theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT antonioperezmartinez theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT maneljuan theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT cristinaeguizabal theraceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT laraherrera raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT silviasantos raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT miguelangelvesga raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT tomascarrascosa raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT juancarlosgarciaruiz raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT antonioperezmartinez raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT maneljuan raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers AT cristinaeguizabal raceofcartherapiescarnkcellsforfightingbcellhematologicalcancers
_version_	1718435237500813312

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

Ejemplares similares